BMGL · Basel Medical Group Ltd Ordinary Shares

Performance Summary

Basel Medical Group Ltd's FY2025 financial results show a significant shift from profitability to a substantial net loss. The company reported a net loss of US$8.36 million (S$10.64 million), compared to a net profit of S$2.07 million in FY2024. This dramatic reversal was primarily caused by a US$8.14 million (S$10.35 million) impairment loss on goodwill related to the acquisition of Bethesda Medical Pte Ltd. Excluding this impairment, the underlying business showed revenue growth of 12.6% to US$8.90 million (S$11.32 million). The company's cash position strengthened to US$2.39 million (S$3.04 million) as of June 30, 2025, from US$1.53 million (S$1.95 million) the prior year, largely due to net proceeds of approximately US$7.25 million from its initial public offering completed in February-March 2025.

Revenue Analysis

Revenue increased by S$1.27 million (12.6%) from S$10.05 million in FY2024 to S$11.32 million (US$8.90 million) in FY2025. This growth came from two sources: the newly acquired Bethesda general practice clinic group contributed S$0.90 million in revenue, while the core orthopedic specialist clinic at Gleneagles saw revenue increase by S$0.37 million (3.7%) to S$10.42 million. Within the specialist clinic segment, revenue from corporate patients increased by S$0.46 million, attributed to a post-COVID rebound in the construction sector leading to more injury-related cases. This was partially offset by a S$0.09 million decrease in revenue from individual walk-in patients. The company served approximately 964 corporate-referred patients and 13,161 individual patients during FY2025.

Margins & Profitability

The company's profitability was severely impacted by the goodwill impairment. Before this impairment and tax, the company reported a loss of US$8.69 million (S$11.05 million), compared to a profit of S$2.40 million in FY2024. Operating expenses increased significantly: employee benefit expenses rose by 75.8% to S$6.40 million due to increased headcount and bonus payments; depreciation expense increased by 123.4% to S$1.18 million mainly from right-of-use assets of the Bethesda group; and other operating expenses increased by 118.2% to S$3.30 million due to exchange losses and professional fees. Consumables, medical supplies and related expenses increased by 13.5% to S$2.55 million, in line with revenue growth.

Cash Flow & Balance Sheet

The company's liquidity position improved during FY2025. Cash and cash equivalents increased to US$2.39 million (S$3.04 million) from US$1.53 million (S$1.95 million). Net cash used in operating activities was US$3.18 million (S$4.04 million), primarily due to increases in trade receivables. Net cash generated from financing activities was US$12.97 million (S$16.50 million), mainly from share issuance proceeds of US$7.67 million (S$9.75 million) and a decrease in amounts due from related parties of US$8.30 million (S$10.56 million). Total assets were US$14.69 million (S$18.68 million), with current assets comprising 71.2%. Total equity attributable to owners was US$4.27 million (S$5.43 million), down from US$5.58 million (S$7.56 million) the prior year.

Outlook

The company's expansion strategy includes broadening service offerings and integrating advanced medical solutions to position itself as a key player in Southeast Asia's healthcare ecosystem. The acquisition of Bethesda Medical represents part of this expansion strategy in Singapore. The company faces several risks including dependence on key medical practitioners, competition in the healthcare sector, regulatory compliance requirements, and cybersecurity risks. As an emerging growth company, it benefits from reduced reporting requirements but faces challenges as a newly public company with additional compliance costs. The company does not expect to pay dividends in the foreseeable future and intends to retain earnings for business development and growth.